RBY 0.00% 0.9¢ rockeby biomed limited

quaterly, page-6

  1. 106 Posts.
    The following are my rough estimates based on the company announcements and some deductions:

    Sales Revenue for the past 3 qtrs were = $199k
    623k pepp tablets (pa) @ 40c (wholesale price) = $249k
    pepp sales have doubled in the past half year therefore the last qtr + this qtr should be $166k - as last qtr was only 85k in total sales revenue (& this contained bird flu test kits etc), then pepp sales should be at least $120k this qtr.
    500k avian flu tests @ $5 = $2.5m

    Therefore sales revenue this quarter of a minimum of $2.62m should be reported - assuming

    1. the wholesale price for pepp tablets is approx 1/3 of the retail price
    2. the sale price of the tests kits are $5 (I have assumed a discounted price due to the bulk order)
    3. the company has received the full money from the 500k avian bird flu tests (if they haven't then I would be concerned that the terms of the sale agreement had not been met - and this will seriously affect the projected short term profitability)

    So if the quarterly comes out with considerably less than $2.62m in sales revenue, I would be seriously concerned that the announcements made by the company were not accurate.

    Any comments?
    Cheers
    KM
 
watchlist Created with Sketch. Add RBY (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.